A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
← catalyst calendarSponsored by Bio-Path Holdings, Inc. (industry) · BPTH — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-05 | actual | When the study began enrolling |
| Primary completion | Apr 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2019-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mantle Cell Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- Cutaneous T-cell Lymphoma (CTCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Hodgkin Lymphoma
- Waldenstrom Macroglobulinemia
- DLBCL
Intervention
- Drug: L-Bcl-2 antisense oligonucleotide — also filed as BP1002
Primary outcomes
what the primary-completion date above is the date OFIdentify Dose Limiting Toxicity (DLT) of BP1002
measured 30 days
Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002
measured 30 days
Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 by identification and grading of
measured 30 days
Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) of escalating doses of BP1002
measured 30 days
Recommended Phase 2 dose (RP2D) of BP1002
measured 210 days
Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration
measured 30 days
Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution
measured 30 days
Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant
measured 30 days
Determine half-life plasma pharmacokinetics (PK) of BP1002
measured 30 days
Determine pharmacokinetics (PK) of BP1002
measured 30 days
Permalink · BPTH's whole pipeline · Catalyst calendar · Every registered study · What changed